FluoGuide A/S (STO:FLUO)

Sweden flag Sweden · Delayed Price · Currency is SEK
41.70
-1.90 (-4.36%)
Mar 23, 2026, 5:20 PM CET
Market Cap712.83M +20.9%
Revenue (ttm)318.79K -42.9%
Net Income-57.18M
EPS-4.07
Shares Out16.35M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,736
Average Volume9,506
Open44.40
Previous Close43.60
Day's Range40.40 - 44.40
52-Week Range28.00 - 47.60
Beta0.42
RSI67.39
Earnings DateFeb 25, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol FLUO
Full Company Profile

Financial Performance

In 2025, FluoGuide's revenue was 220,000, a decrease of -42.86% compared to the previous year's 385,000. Losses were -39.46 million, 36.3% more than in 2024.

Financial numbers in DKK Financial Statements